Gender-affirming hormone therapy and vascular health: walking the line between caution and confidence
Authors' conclusion
This pilot study suggests a more pronounced progression of atherosclerosis in TW undergoing GAHT, detectable particularly through CCTA.
Study context
- Population
- Transgender individuals initiating or continuing gender-affirming hormone therapy (GAHT), Bordeaux University Hospital
- Participants
- 34 individuals
- Exposure
- Transwomen vs transmen on GAHT
- TWn = 17
- TMn = 17reference
- Outcome
- Early cardiovascular (CV) risk modification by imaging (CAC, CCTA, SATUS)
- Follow-up
- 18 months
Methodological detailssingle-centre, pilot study
- Single-centre
- Pilot study
Main finding
As reported in the abstract
Progression of coronary plaque volume (CCTA)
Observational data: associations, not effects.
Further findings
Carotid plaque volume and coronary artery calcium (CAC) score · 18 months
- Both zero at baseline; modest increase in TW, no change in TM
Original publication
Gender-affirming hormone therapy and vascular health: walking the line between caution and confidence. Eur J Prev Cardiol. Published 5 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →